Release date: 3 March 2009
Promoter – Financial Intermediary
The promoter is one of the top 20 pharmaceutical companies in the world and the largest generic pharmaceutical company.
Location
Description
The project concerns financing the R&D for new Active Pharmaceutical Ingredients (APIs), innovative drug compounds and new generic drugs located in Debrecen, Gödöllö and Sajobabony, as well as two related capital expenditure investments in R&D Centres in Debrecen and Gödöllö.
Objectives
The aim of the first, R&D part of the project is the commercialisation of more than 30 new generic compounds up to 2013. The purpose of the capital expenditure investments is to increase the existing R&D infrastructure.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 100 million.
Total cost (Approximate amount)
EUR 200 million.
Environmental aspects
Installations for the R&D Centre in Debrecen will fall under Annex II of the EIA Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC. Whether the competent authorities have required an EIA or not will be verified during appraisal, as well as any actual/possible significant impacts on protected flora and fauna (Habitats and Birds Directives). Compliance of R&D activities with relevant EU legislation in regards to animal testing, clinical trials, etc. will be verified during appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives 2004/18/EC. The promoter carries out competitive international consultations among potential suppliers for goods and services, which is standard practice for this industry.
Status
Signed - 24/09/2009
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).